Datopotamab deruxtecan: A novel antibody drug conjugate for triple-negative breast cancer

Schipilliti F. M., Drittone D., Mazzuca F., La Forgia D., GÜVEN D. C., Rizzo A.

Heliyon, vol.10, no.7, 2024 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 10 Issue: 7
  • Publication Date: 2024
  • Doi Number: 10.1016/j.heliyon.2024.e28385
  • Journal Name: Heliyon
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CAB Abstracts, Food Science & Technology Abstracts, Veterinary Science Database, Directory of Open Access Journals
  • Keywords: ADC, Antibody-drug conjugates, Breast cancer, Dato-DXd, Datopotamab deruxtecan, Triple-negative breast cancer
  • Hacettepe University Affiliated: Yes


Triple negative breast cancer (TNBC) represents the breast cancer subtype with least favorable outcome because of the lack of effective treatment options and its molecular features. Recently, ADCs have dramatically changed the breast cancer treatment landscape; the anti-TROP2 ADC Sacituzumab Govitecan has been approved for treatment of previously treated, metastatic TNBC patients. The novel ADC Datopotecan-deruxtecan (Dato-DXd) has recently shown encouraging results for TNBC. In the current paper, we summarize and discuss available data regarding this TROP-2 directed agent mechanism of action and pharmacologic activity, we describe first results on efficacy and safety of the drug and report characteristics, inclusion criteria and endpoints of the main ongoing clinical trials.